Emilio Bajetta
Overview
Explore the profile of Emilio Bajetta including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
111
Citations
4254
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ignatiadis M, Bailey A, McArthur H, El-Abed S, de Azambuja E, Metzger O, et al.
JAMA
. 2025 Jan;
PMID: 39883436
Importance: Triple-negative breast cancer is an aggressive subtype with a high incidence in young patients, a high incidence in non-Hispanic Black women, and a high risk of progression to metastatic...
2.
Pfeiler G, Hlauschek D, Mayer E, Deutschmann C, Kacerovsky-Strobl S, Martin M, et al.
J Clin Oncol
. 2023 Aug;
41(33):5118-5130.
PMID: 37556775
Purpose: BMI affects breast cancer risk and prognosis. In contrast to cytotoxic chemotherapy, CDK4/6 inhibitors are given at a fixed dose, irrespective of BMI or weight. This preplanned analysis of...
3.
Pusceddu S, Prinzi N, Tafuto S, Ibrahim T, Filice A, Brizzi M, et al.
JAMA Netw Open
. 2022 Feb;
5(2):e220290.
PMID: 35201309
Importance: Data about the optimal timing for the initiation of peptide receptor radionuclide therapy (PRRT) for advanced, well-differentiated enteropancreatic neuroendocrine tumors are lacking. Objective: To evaluate the association of upfront...
4.
Dottorini L, Catena L, Sarno I, Di Menna G, Marte A, Novelli E, et al.
J Geriatr Oncol
. 2018 Oct;
10(2):356-358.
PMID: 30333087
Background: Endocrine therapy is the main treatment in hormonosensitive breast cancer; the most frequent side effects are arthralgia, osteoporosis, depression, dyslipidemia and hypertension. G8 is a simple test developed to...
5.
Dottorini L, Catena L, Sarno I, Di Menna G, Marte A, Bajetta E
Oncology
. 2018 Jul;
94 Suppl 1:6-9.
PMID: 30036862
We report the case of a 50-year-old woman with a triple-negative Ki67 80% breast cancer with liver metastases, who obtained a radiological long-lasting complete response after treatment with eribulin. The...
6.
Pusceddu S, Vernieri C, Di Maio M, Marconcini R, Spada F, Massironi S, et al.
Gastroenterology
. 2018 Apr;
155(2):479-489.e7.
PMID: 29655834
Background & Aims: Metformin seems to have anticancer effects. However, it is not clear whether use of glycemia and metformin affect outcomes of patients with advanced pancreatic neuroendocrine tumors (pNETs)....
7.
Pusceddu S, Barretta F, Trama A, Botta L, Milione M, Buzzoni R, et al.
Endocr Relat Cancer
. 2018 Mar;
25(6):607-618.
PMID: 29559553
No validated prognostic tool is available for predicting overall survival (OS) of patients with well-differentiated neuroendocrine tumors (WDNETs). This study, conducted in three independent cohorts of patients from five different...
8.
Bajetta E, Catena L, Pusceddu S, Spada F, Iannacone C, Sarno I, et al.
Neuroendocrinology
. 2017 Jul;
106(4):307-311.
PMID: 28743120
Background: We previously presented data of this multicentric, phase II study showing that everolimus plus octreotide long-acting repeatable (LAR) for advanced neuroendocrine neoplasms (NENs), in the first line setting, is...
9.
Pietrantonio F, Di Bartolomeo M, Cotsoglou C, Mennitto A, Berenato R, Morano F, et al.
Clin Colorectal Cancer
. 2016 Dec;
16(3):e191-e198.
PMID: 27979717
Background: For borderline resectable colorectal cancer liver metastases (CLM), systemic treatment can help to achieve R0 resection and reduce the risk of relapse. We assessed the role of perioperative triplet...
10.
Di Bartolomeo M, Pietrantonio F, Rulli E, Poli D, Berenato R, Caporale M, et al.
Tumori
. 2016 Apr;
102(4):e15-9.
PMID: 27032700
Purpose: Adjuvant chemotherapy improves survival of patients with gastric cancer. Intergroup Trial of Adjuvant Chemotherapy in Adenocarcinoma of the Stomach (ITACA-S) was a phase III study comparing sequential FOLFIRI followed...